ReviewCureus2025
A Scoping Review of the Methodologies and Reporting Standards in Recent Applications of Artificial Intelligence in Radiomics for Chronic Subdural Hematoma Imaging.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From burr-hole to embolization: unveiling the evolution of chronic subdural hematoma research (2001-2025).Frontiers in neurologyPooled it
- Review
- Structure of Trials Assessing Endovascular Embolization for Brain Arteriovenous Malformations: A Scoping Review.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic subdural hematoma (cSDH) is the accumulation of blood in the subdural space, primarily affecting older adults. Radiomics is a rapidly emerging field that integrates artificial intelligence (AI) with imaging to improve diagnostic precision and prognostic predictions, including hematoma expansion and recurrence. However, the heterogeneous study designs, endpoints, and reporting standards limit its clinical application. This scoping review queried PubMed for studies published before or on December 25, 2024, using terms related to cSDH and AI-based imaging analysis. Inclusion criteria required primary research applying AI to cSDH imaging and reporting prognostic endpoints such as recurrence, expansion, or treatment response. Extracted data included methodological variables, imaging modalities, endpoints of interest, and performance metrics. Most studies used computed tomography (CT) imaging for analysis, with hematoma recurrence being the most frequently evaluated endpoint of interest. However, there was wide inconsistency in the reporting of model performance metrics. Thus, radiomics offers opportunities to improve outcome prediction and treatment planning in cSDH. Future work should focus on defining clinically meaningful endpoints, standardizing metrics, and validating models prospectively to facilitate integration into practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.